Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals
  • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals
  • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals
  • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
  • C07H19/167—Purine radicals with ribosyl as the saccharide radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
  • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
  • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/16—Aptamers
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/30—Chemical structure
  • C12N2310/33—Chemical structure of the base
  • C12N2310/335—Modified T or U

Definitions

• the present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidites and triphosphates derivatives thereof.
• the present disclosure also relates to methods of making and using the same.
• the disclosure includes the use of the modified nucleosides as part of an oligonucleotide or an aptamer.
• modified nucleosides As therapeutic agents, diagnostic agents, and for incorporation into oligonucleotides.
• modified nucleosides such as AZT, ddI, d4T, and others have been used to treat AIDS.
• 5-trifluoromethyl-2′-deoxyuridine is active against herpetic keratitis and 5-iodo-1-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)cytosine has activity against CMV, VZV, HSV-1, HSV-2 and EBV (A Textbook of Drug Design and Development, Povl Krogsgaard-Larsen and Hans Bundgaard, Eds., Harwood Academic Publishers, 1991, Ch. 15).
• Modified nucleosides have shown utility in diagnostic applications.
• the nucleosides are incorporated into DNA in determinable locations, and various diagnostic methods are used to determine the location of the modified nucleosides. These methods include radiolabeling, fluorescent labeling, biotinylation, and strand cleavage.
• An example of strand cleavage involves reacting the nucleoside with hydrazine to yield urea nucleosides, then reacting the urea nucleoside with piperidine to cause strand cleavage (the Maxam-Gilbert method).
• Modified nucleosides have also been incorporated into oligonucleotides.
• Antisense oligonucleotides can bind certain genetic coding regions in an organism to prevent the expression of proteins or to block various cell functions.
• a process known as the SELEX process or systematic Evolution of Ligands for EXponential Enrichment, allows one to identify and produce oligonucleotides (referred to as “aptamers”) that selectively bind target molecules.
• aptamers oligonucleotides
• the SELEX method involves the selection of oligonucleotides from a mixture of candidates to achieve virtually any desired criterion of binding affinity and selectivity.
• the method involves contacting the mixture with a target under conditions favorable for binding (or interacting), partitioning unbound oligonucleotides from oligonucleotides which have bound to (or interacted with) target molecules, dissociating the oligonucleotide-target pairs, amplifying the oligonucleotides dissociated from the oligonucleotide-target pairs to yield a ligand-enriched mixture of oligonucleotides, then reiterating the steps of binding, partitioning, dissociating and amplifying through as many cycles as desired.
• Modified nucleosides can be incorporated into antisense oligonucleotides, ribozymes, and oligonucleotides used in or identified by the SELEX process. These nucleosides can impart in vivo and in vitro stability of the oligonucleotides to endo and exonucleases, alter the charge, hydrophilicity or lipophilicity of the molecule, and/or provide differences in three dimensional structure.
• nucleosides that have been previously described include 2′-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil, backbone modifications, and methylations. Modifications have also included 3′ and 5′ modifications such as capping.
• PCT WO 91/14696 describes a method for chemically modifying antisense oligonucleotides to enhance entry into a cell.
• U.S. Pat. Nos. 5,428,149, 5,591,843, 5,633,361, 5,719,273, and 5,945,527 which are incorporated herein by reference in their entirety, describe modifying pyrimidine nucleosides via palladium coupling reactions.
• a nucleophile and carbon monoxide are coupled to pyrimidine nucleosides containing a leaving group on the 5-position of the pyrimidine ring, preferably forming ester and amide derivatives.
• PCT WO 90/15065 describes a method for making exonuclease-resistant oligonucleotides by incorporating two or more phosphoramidite, phosphoromonothionate and/or phosphorodithionate linkages at the 5′ and/or 3′ ends of the oligonucleotide.
• PCT WO 91/06629 discloses oligonucleotides with one or more phosphodiester linkages between adjacent nucleosides replaced by forming an acetal/ketal type linkage which is capable of binding RNA or DNA.
• nucleosides for therapeutic and diagnostic applications and for inclusion in oligonucleotides.
• oligonucleotides When incorporated in oligonucleotides, it would be advantageous to provide new oligonucleotides that exhibit different high affinity binding to target molecules, and/or show increased resistance to exonucleases and endonucleases than oligonucleotides prepared from naturally occurring nucleosides. It would also be useful to provide nucleotides with modifications that impart a biological activity other than, or in addition to, endonuclease and exonuclease resistance.
• the present disclosure provides 5-position modified uridines of the following general formula:
• carbocyclic sugar analogs can be replaced with carbocyclic sugar analogs, ⁇ -anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside.
• the compounds of the present disclosure can be incorporated into oligonucleotides or aptamers using standard synthetic or enzymatic methods of preparing such compounds.
• Also provided in the present disclosure are methods for producing the compounds of the present disclosure and the compounds produced by said methods.
• a method for preparing a C-5 modified aminocarbonylpyrimidine comprising : reacting a pyrimidine modified at the 5-position with a trifluoroethoxycarbonyl with an amine in the presence of a base; and isolating said C-5 modified aminocarbonylpyrimidine.
• a method for preparing a 3′-phosporamidite of a C-5 modified aminocarbonylpyrimidine comprising: reacting said C-5 modified aminocarbonylpyrimidine with cyanoethyldiisopropyl-chlorophosphoramidite in the presence of a base; and isolating said 3′-phosporamidite.
• a method for preparing a 5′-triphosphate of a C-5 modified aminocarbonylpyrimidine comprising:
• R and X are as defined above, with acetic anhydride in the presence of a base, followed by cleavage of the 5′-DMT group with an acid to form a 3′-acetate of the following structure:
• an aptamer includes mixtures of aptamers, and the like.
• the term “about” represents an insignificant modification or variation of the numerical value such that the basic function of the item to which the numerical value relates is unchanged.
• each when used herein to refer to a plurality of items is intended to refer to at least two of the items. It need not require that all of the items forming the plurality satisfy an associated additional limitation.
• the terms “comprises,” “comprising,” “includes,” “including,” “contains,” “containing,” and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, product-by-process, or composition of matter that comprises, includes, or contains an element or list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, product-by-process, or composition of matter.
• nucleotide refers to a ribonucleotide or a deoxyribonucleotide, or a modified form thereof, as well as an analog thereof.
• Nucleotides include species that include purines (e.g., adenine, hypoxanthine, guanine, and their derivatives and analogs) as well as pyrimidines (e.g., cytosine, uracil, thymine, and their derivatives and analogs).
• the present disclosure provides compounds of the following formula:
• carbocyclic sugar analogs can be replaced with carbocyclic sugar analogs, ⁇ -anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside.
• R, R′′ and X are as defined above.
• Compounds of this general formula are useful for incorporation of the modified nucleoside into an oligonucleotide by chemical synthesis.
• the present disclosure provides compounds of the formula or salts thereof:
• R, R′ and X are as defined above.
• Compounds of this general formula are useful for incorporation of the modified nucleoside into an oligonucleotide by enzymatic synthesis.
• C-5 modified carboxyamideuridine or “C-5 modified aminocarbonyluridine” refers to a uridine with a carboxyamide (—C(O)NH—) modification at the C-5 position of the uridine including, but not limited to, those moieties (R) illustrated above.
• Examples of a C-5 modified carboxyamideuridines include those described in U.S. Pat. Nos. 5,719,273 and 5,945,527, as well as, U.S. Provisional Application Ser. No. 61/422,957 (the '957 application), filed Dec.
• Representative C-5 modified pyrimidines include: 5-(N-benzylcarboxyamide)-2′-deoxyuridine (BndU), 5-(N-benzylcarboxyamide)-2′-O-methyluridine, 5-(N-benzylcarboxyamide)-2′-fluorouridine, 5-(N-isobutylcarboxyamide)-2′-deoxyuridine (iBudU), 5-(N-isobutylcarboxyamide)-2′-O-methyluridine, 5-(N-isobutylcarboxyamide)-2′-fluorouridine, 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine (TrpdU), 5-(N-tryptaminocarboxyamide)-2′-O-methyluridine, 5-(N-tryptaminocarboxyamide)-2′-fluorouridine, 5-(N-[1-(3-trifluorouridine, 5-(N-[1-(3-trifluorour
• C-5 modified aminocarbonyluridines include the following compounds as well as the 5′-triphosphates and 3′-phosphoramidites and salts thereof of said compounds, the syntheses of which are described in Examples 1-5.
• a corresponding salt of the compound for example, a pharmaceutically-acceptable salt.
• a pharmaceutically-acceptable salt examples are discussed in Berge et al. “Pharmaceutically Acceptable Salts” (1977) J. Pharm. Sci. 66:1-19.
• a salt may be formed with a suitable cation.
• suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al +3 .
• Suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R X+ , NH 2 R X 2 + , NHR X 3 + , NR X 4 + ).
• Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperizine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
• An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
• a salt may be formed with a suitable anion.
• suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
• Suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric.
• a reference to a particular compound also includes salt forms thereof.
• the instant disclosure provides methods for using the modified nucleosides described herein, either alone or in combination with other modified nucleosides and/or naturally occurring nucleosides, to prepare modified oligonucleotides.
• the automated synthesis of oligodeoxynucleosides is routine practice in many laboratories (see e.g., Matteucci, M. D. and Caruthers, M. H., (1990) J. Am. Chem. Soc., 103:3185-3191, the contents of which are hereby incorporated by reference). Synthesis of oligoribonucleosides is also well known (see e.g. Scaringe, S. A., et al., Nucleic Acids Res.
• the phosphoramidites are useful for incorporation of the modified nucleoside into an oligonucleotide by chemical synthesis
• the triphosphates are useful for incorporation of the modified nucleoside into an oligonucleotide by enzymatic synthesis.
• the terms “modify,” “modified,” “modification,” and any variations thereof, when used in reference to an oligonucleotide means that at least one of the four constituent nucleotide bases (i.e., A, G, T/U, and C) of the oligonucleotide is an analog or ester of a naturally occurring nucleotide.
• the modified nucleotide confers nuclease resistance to the oligonucleotide. Additional modifications can include backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine, and the like. Modifications can also include 3′ and 5′ modifications, such as capping.
• modifications can include substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and those with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, and those with modified linkages (e.g., alpha anomeric nucleic acids, etc.).
• internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and those with charged linkages
• any of the hydroxyl groups ordinarily present on the sugar of a nucleotide may be replaced by a phosphonate group or a phosphate group; protected by standard protecting groups; or activated to prepare additional linkages to additional nucleotides or to a solid support.
• the 5′ and 3′ terminal OH groups can be phosphorylated or substituted with amines, organic capping group moieties of from about 1 to about 20 carbon atoms, polyethylene glycol (PEG) polymers in one embodiment ranging from about 10 to about 80 kDa, PEG polymers in another embodiment ranging from about 20 to about 60 kDa, or other hydrophilic or hydrophobic biological or synthetic polymers.
• Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including 2′-O-methyl, 2′-O-allyl, 2′-O-ethyl, 2′-O-propyl, 2′-O—CH 2 CH 2 OCH 3 , 2′-fluoro- or 2′-azido, carbocyclic sugar analogs, ⁇ -anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside.
• analogous forms of ribose or deoxyribose sugars that are generally known in the art, including 2′-O-methyl, 2′-O-allyl, 2′-O-ethyl, 2′-O-propyl, 2′-
• one or more phosphodiester linkages may be replaced by alternative linking groups.
• alternative linking groups include embodiments wherein phosphate is replaced by P(O)S (“thioate”), P(S)S (“dithioate”), (O)NR X 2 (“amidate”), P(O) R X , P(O)OR X ′, CO or CH 2 (“formacetal”), in which each R X or R X ′ are independently H or substituted or unsubstituted alkyl (C1-C20) optionally containing an ether (—O—) linkage, aryl, alkenyl, cycloalky, cycloalkenyl or araldyl.
• a modification to the nucleotide structure can be imparted before or after assembly of a polymer.
• a sequence of nucleotides can be interrupted by non-nucleotide components.
• a polynucleotide can be further modified after polymerization, such as by conjugation with a labeling component.
• nucleic acid As used herein, “nucleic acid,” “oligonucleotide,” and “polynucleotide” are used interchangeably to refer to a polymer of nucleotides and include DNA, RNA, DNA/RNA hybrids and modifications of these kinds of nucleic acids, oligonucleotides and polynucleotides, wherein the attachment of various entities or moieties to the nucleotide units at any position are included.
• polynucleotide oligonucleotide
• nucleic acid include double- or single-stranded molecules as well as triple-helical molecules.
• nucleic acid, oligonucleotide, and polynucleotide are broader terms than the term aptamer and, thus, the terms nucleic acid, oligonucleotide, and polynucleotide include polymers of nucleotides that are aptamers but the terms nucleic acid, oligonucleotide, and polynucleotide are not limited to aptamers.
• the term “at least one nucleotide” when referring to modifications of a nucleic acid refers to one, several, or all nucleotides in the nucleic acid, indicating that any or all occurrences of any or all of A, C, T, G or U in a nucleic acid may be modified or not.
• the instant disclosure methods for using the modified nucleosides described herein, either alone or in combination with other modified nucleosides and/or naturally occurring nucleosides, to prepare aptamers and SOMAmers (described below).
• the aptamers and SOMAmers are prepared using the general SELEX or improved SELEX process as described below.
• nucleic acid ligand As used herein, “nucleic acid ligand,” “aptamer,” “SOMAmer,” and “clone” are used interchangeably to refer to a non-naturally occurring nucleic acid that has a desirable action on a target molecule.
• a desirable action includes, but is not limited to, binding of the target, catalytically changing the target, reacting with the target in a way that modifies or alters the target or the functional activity of the target, covalently attaching to the target (as in a suicide inhibitor), and facilitating the reaction between the target and another molecule.
• the action is specific binding affinity for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to the nucleic acid ligand through a mechanism which is independent of Watson/Crick base pairing or triple helix formation, wherein the aptamer is not a nucleic acid having the known physiological function of being bound by the target molecule.
• Aptamers to a given target include nucleic acids that are identified from a candidate mixture of nucleic acids, where the aptamer is a ligand of the target, by a method comprising: (a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to other nucleic acids in the candidate mixture can be partitioned from the remainder of the candidate mixture; (b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and (c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, whereby aptamers of the target molecule are identified.
• an aptamer for its target means that the aptamer binds to its target generally with a much higher degree of affinity than it binds to other, non-target, components in a mixture or sample.
• An “aptamer,” “SOMAmer,” or “nucleic acid ligand” is a set of copies of one type or species of nucleic acid molecule that has a particular nucleotide sequence.
• An aptamer can include any suitable number of nucleotides. “Aptamers” refer to more than one such set of molecules. Different aptamers can have either the same or different numbers of nucleotides. Aptamers may be DNA or RNA and may be single stranded, double stranded, or contain double stranded or triple stranded regions.
• a “SOMAmer” or Slow Off-Rate Modified Aptamer refers to an aptamer having improved off-rate characteristics. SOMAmers can be generated using the improved SELEX methods described in U.S. Publication No. 20090004667, entitled “Method for Generating Aptamers with Improved Off-Rates.”.
• protein is used synonymously with “peptide,” “polypeptide,” or “peptide fragment.”
• a “purified” polypeptide, protein, peptide, or peptide fragment is substantially free of cellular material or other contaminating proteins from the cell, tissue, or cell-free source from which the amino acid sequence is obtained, or substantially free from chemical precursors or other chemicals when chemically synthesized.
• SELEX and “SELEX process” are used interchangeably herein to refer generally to a combination of (1) the selection of nucleic acids that interact with a target molecule in a desirable manner, for example binding with high affinity to a protein, with (2) the amplification of those selected nucleic acids.
• the SELEX process can be used to identify aptamers with high affinity to a specific target molecule or biomarker.
• SELEX generally includes preparing a candidate mixture of nucleic acids, binding of the candidate mixture to the desired target molecule to form an affinity complex, separating the affinity complexes from the unbound candidate nucleic acids, separating and isolating the nucleic acid from the affinity complex, purifying the nucleic acid, and identifying a specific aptamer sequence.
• the process may include multiple rounds to further refine the affinity of the selected aptamer.
• the process can include amplification steps at one or more points in the process. See, e.g., U.S. Pat. No.
• the SELEX process can be used to generate an aptamer that covalently binds its target as well as an aptamer that non-covalently binds its target. See, e.g., U.S. Pat. No. 5,705,337 entitled “Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Chemi-SELEX.”
• the SELEX process can be used to identify high-affinity aptamers containing modified nucleotides that confer improved characteristics on the aptamer, such as, for example, improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX process-identified aptamers containing modified nucleotides are described in U.S. Pat. No. 5,660,985, entitled “High Affinity Nucleic Acid Ligands Containing Modified Nucleotides,” which describes oligonucleotides containing nucleotide derivatives chemically modified at the 5′- and 2′-positions of pyrimidines. U.S. Pat. No.
• SELEX can also be used to identify aptamers that have desirable off-rate characteristics. See U.S. Patent Publication No. 20090004667, entitled “Method for Generating Aptamers with Improved Off-Rates,” which is incorporated herein by reference in its entirety, describes improved SELEX methods for generating aptamers that can bind to target molecules. Methods for producing aptamers and photoaptamers having slower rates of dissociation from their respective target molecules are described.
• the methods involve contacting the candidate mixture with the target molecule, allowing the formation of nucleic acid-target complexes to occur, and performing a slow off-rate enrichment process wherein nucleic acid-target complexes with fast dissociation rates dissociate and do not reform, while complexes with slow dissociation rates remain intact. Additionally, the methods include the use of modified nucleotides in the production of candidate nucleic acid mixtures to generate aptamers with improved off-rate performance (see U.S. Patent Publication No. 20090098549, entitled “SELEX and PhotoSELEX”). (See also U.S. Pat. No. 7,855,054 and U.S. Patent Publication No. 20070166740). Each of these applications is incorporated herein by reference in its entirety.
• Target or “target molecule” or “target” refers herein to any compound upon which a nucleic acid can act in a desirable manner.
• a target molecule can be a protein, peptide, nucleic acid, carbohydrate, lipid, polysaccharide, glycoprotein, hormone, receptor, antigen, antibody, virus, pathogen, toxic substance, substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth factor, cell, tissue, any portion or fragment of any of the foregoing, etc., without limitation. Virtually any chemical or biological effector may be a suitable target. Molecules of any size can serve as targets.
• a target can also be modified in certain ways to enhance the likelihood or strength of an interaction between the target and the nucleic acid.
• a target can also include any minor variation of a particular compound or molecule, such as, in the case of a protein, for example, minor variations in amino acid sequence, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component, which does not substantially alter the identity of the molecule.
• a “target molecule” or “target” is a set of copies of one type or species of molecule or multimolecular structure that is capable of binding to an aptamer.
• “Target molecules” or “targets” refer to more than one such set of molecules. Embodiments of the SELEX process in which the target is a peptide are described in U.S. Pat. No. 6,376,190, entitled “Modified SELEX Processes Without Purified Protein.”
• the C-5 position modified aminocarbonylpyrimidines of the instant disclosure are prepared by reacting a pyrimidine modified at the 5-position with a trifluoroethoxycarbonyl with an amine in the presence of a base; and isolating said C-5 modified aminocarbonylpyrimidine.
• the trifluoroethoxycarbonylpyrimidine is selected from the group of compounds including, but not limited to compounds having the following structure:
• the amine is selected from the group including, but not limited to compounds of the formula RNH 2 , wherein
• the amine is selected from the group consisting of:
• the base is a tertiary amine selected from the group consisting of triethylamine, diisopropylamine and the like.
• the present disclosure also provides a method for the synthesis of a 3′-phosporamidite of a C-5 modified aminocarbonylpyrimidine comprising: reacting said C-5 modified aminocarbonylpyrimidine with cyanoethyldiisopropyl-chlorophosphoramidite in the presence of a base ; and isolating said 3′-phosporamidite.
• the C-5 modified aminocarbonylpyrimidine has the following structure:
• the base is a tertiary amine selected from the group consisting of consisting of triethylamine, diisopropylamine and the like.
• the present disclosure also provides a method for the synthesis of a 5′-triphosphate of a C-5 modified aminocarbonylpyrimidine comprising:
• R and X are as defined above, with acetic anhydride in the presence of a base, followed by cleavage of the 5′-DMT group with an acid to form a 3′-acetate of the following structure:
• the base used is selected from the group including, but not limited to a tertiary amine. In some embodiments the base is pyridine.
• the acid used in step a is selected from the group including, but not limited to dichloroacetic acid, trichloroacetic acid and 1,1,1,3,3,3-hexafluoro-2-propanol.
• the trifluoroethoxycarbonylpyrimidine has the following structure:
• this compound is formed by the reaction of compound (7) of Scheme 2 with carbon monoxide and trifluoroethanol in the presence of a palladium catalyst and a base.
• the base is selected from the group including, but not limited to a tertiary amine selected from triethylamine and the like.
• the present disclosure includes compounds prepared by each of the above described methods.
• 5′-O-Dimethoxytrityl-5-(4-fluorobenzylaminocarbonyl)-2′-deoxyuridine (3a).
• the starting material, 5′-O-dimethoxytrityl-5-trifluoroethoxycarbonyl-2′-deoxyuridine (1) was prepared by the procedure of Matsuda et al (Nomura, Y.; Ueno, Y.; Matsuda, A. Nucleic Acids Research 1997, 25:2784-2791; Ito, T., Ueno, Y.; Matsuda, A. Nucleic Acids Research 2003, 31:2514-2523).
• the nucleoside (3a) (3.00 g, 4.4 mmol) was dissolved in a solution of anhydrous pyridine (30 mL) and acetic anhydride (3 mL). The solution was stirred overnight and concentrated in vacuo to yield the 3′-O-acetyl-nucleoside. Residual solvent was removed by co-evaporation with anhydrous toluene (10 mL). The residue was dissolved in anhydrous dichloromethane (10 mL) and treated with 3% trichloroacetic acid in dichloromethane (58 mL). The red solution was stirred overnight, during which time the product crystallized.
• the compound (5b) was prepared from (4b), by the procedure described for (5a) and isolated by precipitation from a mixture of dichloromethane and ethyl acetate as a white solid (1.27 g, 73% yield).
• 1 H-NMR (CDCl 3 ) ⁇ 1.57-2.02 (4H, m), 2.12 (3H, s), 2.46-2.50 (2H, m), 3.03 (1H, bs), 3.43-3.64 (2H, m), 3.75-3.97 (2H, m), 3.78-4.10 (3H.
• the compound (5c) was prepared from (4c), by the procedure described for (5a), and isolated by precipitation from a mixture of dichloromethane and diethyl ether as a slightly orange solid (1.35 g, 77% yield).
• 1 H-NMR (CDCl 3 ) ⁇ 1.57-2.03 (4H, m), 2.12 (3H, s), 2.47-2.51 (2H, m), 2.98 (1H, bs), 3.40-3.68 (2H, m), 3.78-3.95 (2H, m), 3.90-4.12 (3H.
• the nucleoside (3d) (1.00 g, 1.37 mmol) was dissolved in a solution of anhydrous pyridine (10 mL) and acetic anhydride (1 mL). The solution was stirred overnight and concentrated in vacuo to yield the 3′-O-acetyl-nucleoside. Residual solvent was removed by coevaporation with anhydrous toluene (10 mL). The residue was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (20 mL) (Leonard, N. J. Tetrahedron Letters, 1995, 36:7833) and heated at approximately 50° C. for 3 hours. Complete cleavage of the DMT group was confirmed by tic.
• the compound (5e) was prepared as described for (5d) except that the product crystallized directly when the DMT-cleavage reaction was poured into methanol.
• the diacetyl nucleoside (5e) was isolated by filtration as a white solid (0.55 g, 78% yield).
• the 3′-O-acetyl-nucleosides (5a-d) were also synthesized by an alternative route (Scheme 2) from the starting material, 3′-O-acetyl-5′-O-dimethoxytrityl-5-iodo-2′-deoxyuridine (7) (Vaught, J. D., Bock, C., Carter, J., Fitzwater, T., Otis, M., Schneider, D., Rolando, J., Waugh, S., Wilcox, S. K., Eaton, B. E. J. Am. Chem. Soc. 2010, 132, 4141-4151).
• 3′-O-Acetyl-5′-O-dimethoxytrityl-5-(2,2,2-trifluoroethoxycarbonyl)-2′-deoxyuridine 8′-O-Acetyl-5′-O-dimethoxytrityl-5-(2,2,2-trifluoroethoxycarbonyl)-2′-deoxyuridine (8).
• a 500 mL heavy-walled glass pressure reactor was filled with argon and charged with 3′-O-acetyl-5′-O-dimethoxytrityl-5-iodo-2′-deoxyuridine (7) (15.9 g, 22.8 mmol), anhydrous acetontirile (200 mL), triethylamine (7.6 mL, 54 7 mmol), and 2,2,2-trifluoroethanol (16.4 mL, 228 mmol).
• 5-(4-Fluorobenzylaminocarbonyl)-2′-deoxyuridine-5′-O-triphosphate (tris-triethylammonium salt) (6a).
• the triphosphate (6a) was synthesized from the 3′-O-acetyl-nucleoside (5a) by the procedure of Ludwig and Eckstein (Ludwig, J. and Eckstein, F. J. Org. Chem. 1989, 54:631) at 500 ⁇ mol-scale (5 ⁇ ).
• Ludwig and Eckstein Lidwig, J. and Eckstein, F. J. Org. Chem. 1989, 54:631
• the crude triphosphate product after ammonolysis and evaporation, was purified by anion exchange chromatography, as described in the General Procedure (below).
• Nucleoside triphosphates were purified via anion exchange chromatography using an HPLC column packed with Source Q resin (GE Healthcare), installed on a preparative HPLC system, with detection at 278 nm.
• the linear elution gradient employed two buffers, (buffer A: 10 mM triethylammonium bicarbonate/10% acetonitrile, and buffer B: 1 M triethylammonium bicarbonate/10% acetonitrile), with the gradient running at ambient temperature from low buffer B content to high buffer B over the course of the elution.
• the desired product was typically the final material to elute from the column and was observed as a broad peak spanning approximately ten to twelve minutes retention time (early eluting products included a variety of reaction by-products, the most significant being the nucleoside diphosphate).
• Several fractions were collected during product elution. Fraction was analyzed by reversed phase HPLC on a Waters 2795 HPLC with a Waters Symmetry column (PN: WAT054215). Pure product-containing fractions (typically >90%) were evaporated in a Genevac VC 3000D evaporator to afford colorless to light tan resins. Fractions were reconstituted in deionized water and pooled for final analysis.
• the crude product (6a) was dissolved in approximately 5 mL of buffer A (Table 1: prep-HPLC Conditions 1). Each purification injection consisted of a filtered aliquot of approximately 1 mL of this solution injected into a Waters 625 HPLC with a 486 detector fitted with a Resource Q 6mL column (GE Healthcare product code: 17-1179-01) with a mobile phase gradient of 0%-100% buffer B in a 50 minute elution at 12 mL/minute.
• (6a) [ ⁇ est. 13,700 cm ⁇ 1 M ⁇ 1 ] the isolated purified product was 130 ⁇ mol (26% yield).

Priority Applications (12)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=44798979

Family Applications (7)

Family Applications After (6)

Country Status (23)

Cited By (9)

Families Citing this family (48)

Citations (2)

Family Cites Families (95)

• 2011
  • 2011-04-12 SG SG2012074647A patent/SG184497A1/en unknown
  • 2011-04-12 ES ES11769451.3T patent/ES2667491T3/es active Active
  • 2011-04-12 SG SG2014006522A patent/SG2014006522A/en unknown
  • 2011-04-12 CA CA2797188A patent/CA2797188C/fr active Active
  • 2011-04-12 KR KR1020127026771A patent/KR20130043099A/ko not_active Application Discontinuation
  • 2011-04-12 MY MYPI2012004319A patent/MY160608A/en unknown
  • 2011-04-12 JP JP2013505056A patent/JP5901610B2/ja active Active
  • 2011-04-12 EP EP11769451.3A patent/EP2558478B1/fr active Active
  • 2011-04-12 CA CA2793451A patent/CA2793451A1/fr not_active Abandoned
  • 2011-04-12 ES ES17200661T patent/ES2905656T3/es active Active
  • 2011-04-12 JP JP2013505029A patent/JP6012591B2/ja active Active
  • 2011-04-12 MX MX2012011779A patent/MX2012011779A/es not_active Application Discontinuation
  • 2011-04-12 WO PCT/US2011/032017 patent/WO2011130195A1/fr active Application Filing
  • 2011-04-12 EP EP17200661.1A patent/EP3345915B1/fr active Active
  • 2011-04-12 US US13/085,256 patent/US20110275794A1/en not_active Abandoned
  • 2011-04-12 CN CN201610828700.9A patent/CN107033204A/zh active Pending
  • 2011-04-12 NO NO11769451A patent/NO2558478T3/no unknown
  • 2011-04-12 CN CN201180018781.1A patent/CN102858990B/zh not_active Expired - Fee Related
  • 2011-04-12 SG SG2012068565A patent/SG184089A1/en unknown
  • 2011-04-12 BR BR112012025872A patent/BR112012025872B8/pt active IP Right Grant
  • 2011-04-12 AR ARP110101235A patent/AR081452A1/es unknown
  • 2011-04-12 TW TW100112666A patent/TWI505833B/zh not_active IP Right Cessation
  • 2011-04-12 UA UAA201212806A patent/UA105290C2/ru unknown
  • 2011-04-12 DK DK11769451.3T patent/DK2558478T3/en active
  • 2011-04-12 EP EP11769393.7A patent/EP2558586B1/fr active Active
  • 2011-04-12 KR KR1020127029502A patent/KR101842269B1/ko active IP Right Grant
  • 2011-04-12 NZ NZ602618A patent/NZ602618A/en not_active IP Right Cessation
  • 2011-04-12 ES ES11769393.7T patent/ES2610159T3/es active Active
  • 2011-04-12 EA EA201291034A patent/EA022429B1/ru not_active IP Right Cessation
  • 2011-04-12 US US13/634,618 patent/US8598140B2/en active Active
  • 2011-04-12 CN CN201180028946.3A patent/CN102985435B/zh active Active
  • 2011-04-12 CN CN201410340470.2A patent/CN104069512A/zh active Pending
  • 2011-04-12 BR BR122021003805A patent/BR122021003805B8/pt active IP Right Grant
  • 2011-04-12 MX MX2012011771A patent/MX2012011771A/es active IP Right Grant
  • 2011-04-12 WO PCT/US2011/032143 patent/WO2011130289A1/fr active Application Filing
  • 2011-04-12 KR KR1020187006712A patent/KR101952671B1/ko active IP Right Grant
  • 2011-04-12 KR KR1020197004119A patent/KR102185779B1/ko active IP Right Grant
  • 2011-04-12 AU AU2011240774A patent/AU2011240774B2/en not_active Ceased
  • 2011-04-12 AU AU2011240677A patent/AU2011240677B2/en active Active
  • 2011-04-12 MX MX2020003168A patent/MX2020003168A/es unknown
  • 2011-04-12 CA CA3066785A patent/CA3066785A1/fr active Pending
  • 2011-10-11 TW TW109100780A patent/TW202019943A/zh unknown
  • 2011-10-11 TW TW105113101A patent/TWI593701B/zh active
  • 2011-10-11 TW TW106114660A patent/TWI643864B/zh active
  • 2011-10-11 TW TW107132304A patent/TWI671309B/zh active
  • 2011-10-11 TW TW108120336A patent/TWI684596B/zh active
• 2012
  • 2012-10-10 IL IL222339A patent/IL222339A/en active IP Right Grant
  • 2012-10-12 CO CO12181026A patent/CO6630139A2/es unknown
• 2013
  • 2013-11-01 US US14/069,798 patent/US9163056B2/en active Active
• 2015
  • 2015-03-06 HK HK15102316.6A patent/HK1201740A1/xx unknown
  • 2015-09-08 US US14/847,150 patent/US20150376223A1/en not_active Abandoned
  • 2015-10-12 IL IL242038A patent/IL242038A/en active IP Right Grant
• 2016
  • 2016-03-04 JP JP2016041782A patent/JP6352324B2/ja active Active
  • 2016-04-04 US US15/090,406 patent/US20160355540A1/en not_active Abandoned
• 2017
  • 2017-06-06 IL IL252703A patent/IL252703A/en active IP Right Grant
  • 2017-07-14 US US15/650,281 patent/US10221207B2/en active Active
  • 2017-11-30 IL IL256014A patent/IL256014B/en active IP Right Grant
  • 2017-11-30 IL IL256013A patent/IL256013B/en active IP Right Grant
• 2018
  • 2018-02-28 JP JP2018034436A patent/JP7025818B2/ja active Active
  • 2018-09-20 HK HK18112104.8A patent/HK1252803A1/zh unknown
• 2019
  • 2019-01-22 US US16/254,127 patent/US20190233461A1/en not_active Abandoned

Patent Citations (2)

Also Published As

Similar Documents

Legal Events